Summary
Thein vitro activities of taxol and taxotere in comparison with cisplatin and doxorubicin were assessed in 30 primary tumor cultures from human breast cancers. Both taxanes were much more potent than cisplatin and doxorubicin. Taxotere was 3.1; 296, and 9.6-fold more cytotoxic than taxol, cisplatin, and doxorubicin respectively. The cytotoxic activity observed in our experiments confirms the potential clinical relevance of the two taxanes in the management of breast cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assemblyin vitro by taxol. Nature 22: 665–667, 1979
Wani MC, Taylor HL, Wall ME: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent fromTaxus brevifolia. Am Chem Soc 93: 2325–2327, 1971
National Cancer Institute Clinical Brochure: Taxol (NSC 125973). Division of Cancer Treatment, NCI, Bethesda, MD 1991
Denis JN, Greene AE: A highly efficient approach to natural taxol. J Am Chem Soc 110: 5917–5919, 1988
Mangatal L, Adeline MT, Guenard D: Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 45: 4177–4190, 1989
Ringel I, Horwitz SP: Studies with RP56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288–291, 1991
Bissery MC, Guenard D, Gueritte-Voegelein F: Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845–4852, 1991
Stampfer MR, Hallowes RC, Hackett AJ: Growth of normal human mammary cells in culture.In Vitro Cell Dev Biol 16: 415–425, 1980
Smith HS, Lan S, Ceriani R, Hackett AJ, Stampfer MR: Clonal proliferation of cultured nonmalignant and malignant human breast epithelia. Cancer Res 41: 4637–4643, 1981
Stampfer MR, Hackett AJ, Hancock MC, Leung JP, Edgington TS, Smith HS: Growth of human mammary epithelium in culture and expression of tumor specific properties. Cold Spring Harbor Symposium on Cellular Proliferation 9: 819–929, 1982
E.O.R.T.C. Breast Cancer Cooperative Group: Revision of the standards for the assessment of the hormone receptors in human breast cancer. Eur J Cancer 16: 1513–1515, 1980
Silvestrini R, Daidone MG, Valentinis B, Ferraris C, DiRe E, Raspagliesi F, Landoni F, Scarfone G, Bolis G: Potential of cell kinetics in the managment of patients with ovarian cancers. Eur J Cancer 28: 386–390, 1992
Amadori D, Bonaguri C, Nanni O, Gentilini P, Lundi N, Zoli W, Riccobon A, Vio A, Magni E, Saragoni A: Cell kinetics and hormonal features in relation to pathological stage in breast cancer. Breast Cancer Res Treat 18: 19–25, 1991
Smith HS, Lippman ME, Hiller AJ, Stampfer MR, Hackett AJ: Response to doxorubicin of cultured normal and malignant mammary epithelial cells. J Natl Cancer Inst 74: 341–348, 1985
Smith HS, Zoli W, Lippman ME, Howlett A, Volpi A, Amadori D: Development and application of a highly efficientin vitro assay for predicting the chemosensitivity of human breast cancers. In: Amadori D, Ravaioli A, Ridolfi R (eds) Strategies in cancer medical therapy: biological bases and clinical implication, 1989
Smith HS, Zoli W, Volpi A, Hiller A, Lippman ME, Swain S, Nayall B, Dollbaum C, Hackett AJ, Amadori D: Preliminary correlations of clinical outcome within vitro chemosensitivity of second passage human breast cancer cells. Cancer Res 50: 2943–2948, 1990
Zoli W, Volpi A, Bonaguri C, Riccobon A, Savini S, Brizio R, Saragoni A, Medri L, Marra GA, Amadori D: An efficient method for culturing human breast cancer to evaluate antiblastic drug activityin vitro: experience on 136 primary cancers and on 116 recurrences. Breast Cancer Res Treat 17: 231–238, 1990
Alberts DS, Chen HS: Tabular summary of pharmacokinetic parameters relevant toin vitro drug testing. In: Salmon S (ed) Cloning of human tumor stem cells. Liss, New York, 1980, pp 351–359
Wiernik PII, Schwartz EL, Einzing A, Strauman II, Lipton RB, Dutcher JP: Phase I trial of taxol in patients with advanced malignancies. Cancer Treat Rep 71: 1171–1177, 1987
Koechli OR, Sevin BU, Perras JP, Chou TC, Angioli R, Steren A, Untch M, Averette HE: Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell Viability Assay. Breast Cancer Res Treat 28: 21–27, 1993
Irvin RJ, Burris H, Eckardt J, Rodriguez G, Weiss G, Koeller J, Von Hoff DD, Kuhn JG: Pharmacokinetics of a 6 hr Taxotere infusion (RP56976, NSC628503). Proc Am Soc Clin Oncol 11: 108a, 1992
Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D Jr, Jaiyesimi I, Vreeland F, Bayssas MMG, Raber MN: Phase I trial of taxotere: five-day schedule. JNCI 84: 1781–1788, 1992
Silvestrini R, Zaffaroni N, Orlandi L, Saro O:In vitro cytotoxic activity of taxol and taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells 11: 528–535, 1993
Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P: Relationship between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992–998, 1991
Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum CH, Aapro MS, Bissery MC, Rastetter J, Hanauske AR: Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumor cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer (in press)
Kelland LR, Abel G: Comparativein vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444–450, 1992
Eisenhauer E, Lofters W, Norris B, Muldal A, Letendre F, Vandenburg T, Verma S: Phase II study of taxotere as first line chemotherapy for metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. (Abstract) Proc ASCO 12: 64, 1993
Seidman AD, Hudis C, Crown JPA, Balmaceda C, Lebwohl D, Currie V, Gilewski T, Hakes T, Robles M, Klem K, Lepore J, Norton L: Phase II evaluation of taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer. (Abstract) Proc ASCO 12: 63, 1993
Fumoleau P, Chevallier B, Kerbrat T, Dieras V, De Bail N, Bayssas M, Van Glabbeke M: First line chemotherapy with taxotere in advanced breast cancer: A phase II study of the EORTC Clinical Screening Group. (Abstract) Proc ASCO 12: 56, 1993
Rowinsky EK, Onetto N, Canetta RM, Arbuck SG: Taxol: The first of taxanes, an important new class of antitumor agents. Semin Oncol 19: 646–662, 1992
Holmes FA, Walters RS, Theriault RL: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–18005, 1991
Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19: 670–686, 1992
Bisset D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ: Phase I pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523–527, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zoli, W., Flamigni, A., Frassineti, G.L. et al. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res Tr 34, 63–69 (1995). https://doi.org/10.1007/BF00666492
Issue Date:
DOI: https://doi.org/10.1007/BF00666492